YOLK SAC TUMOR
Clinical trials for YOLK SAC TUMOR explained in plain language.
Never miss a new study
Get alerted when new YOLK SAC TUMOR trials appear
Sign up with your email to follow new studies for YOLK SAC TUMOR, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
Genom att skicka in godkänner du våra Användarvillkor
-
Supercharged immune cells take on hard-to-treat cancers
Disease control Recruiting nowThis early-phase trial tests a new type of immunotherapy for adults with solid tumors that have a protein called GPC3 on their surface. Researchers take a patient's own T cells, add genes to help them recognize and attack GPC3-positive cancer cells, and also include a safety swit…
Matched conditions: YOLK SAC TUMOR
Phase: PHASE1 • Sponsor: Baylor College of Medicine • Aim: Disease control
Last updated May 26, 2026 09:54 UTC
-
Engineered immune cells take on childhood cancers in new trial
Disease control Recruiting nowThis early-stage trial tests a new treatment for children and young adults with solid tumors that have come back or not responded to standard therapy. The treatment uses the patient's own immune cells, which are modified in a lab to better recognize and attack cancer cells. The m…
Matched conditions: YOLK SAC TUMOR
Phase: PHASE1 • Sponsor: Seattle Children's Hospital • Aim: Disease control
Last updated May 26, 2026 09:51 UTC
-
Engineered immune cells take on childhood cancers in first human test
Disease control Recruiting nowThis early-phase trial tests a new treatment called CARE T cells for children whose solid tumors (like liver cancer or Wilms tumor) have returned or not responded to standard care. The treatment involves taking a patient's own immune cells, adding special genes to help them recog…
Matched conditions: YOLK SAC TUMOR
Phase: PHASE1 • Sponsor: Baylor College of Medicine • Aim: Disease control
Last updated May 22, 2026 14:04 UTC
-
New hope for rare cancers: immunotherapy trial targets tumors regardless of origin
Disease control Recruiting nowThis study tests the drug nivolumab in people with advanced rare cancers that have a specific marker (PD-L1). The goal is to see if the drug can shrink or control tumors for at least 12 months. About 28 adults who have not responded to standard treatments will take part.
Matched conditions: YOLK SAC TUMOR
Phase: PHASE2 • Sponsor: Instituto do Cancer do Estado de São Paulo • Aim: Disease control
Last updated May 18, 2026 12:13 UTC
-
Major study aims to unlock secrets of childhood germ cell tumors
Knowledge-focused Recruiting nowThis study follows over 1,100 children and teens diagnosed with germ cell tumors to learn about short- and long-term side effects from treatment, especially hearing loss. Researchers will also analyze tumor genetics to find patterns that could better predict which patients need m…
Matched conditions: YOLK SAC TUMOR
Sponsor: Children's Oncology Group • Aim: Knowledge-focused
Last updated May 26, 2026 10:02 UTC